Pfizer’s TUKYSA Shows Strong Benefit in First-Line HER2+ Breast Cancer
NEW YORK, Oct. 14, 2025 – Pfizer Inc. (NYSE: PFE) announced positive topline results from the Phase 3 HER2CLIMB-05...
cancer therapy
Advertisement
BeOne Medicines’ Sonrotoclax Gets FDA Breakthrough Status
October 13, 2025 | USA – BeOne Medicines, a clinical-stage biopharmaceutical company, announced that its investigational drug Sonrotoclax has...
Eisai Highlights Groundbreaking Oncology Data at ESMO 2025 Congress
NUTLEY, N.J., Oct. 2, 2025 — Eisai Inc. announced today the presentation of its expansive oncology portfolio at the...
FDA Approves Eli Lilly’s Inluriyo for ESR1-Mutated Breast Cancer
Indianapolis, Sept. 25, 2025 – In a landmark advancement for breast cancer treatment, the U.S. Food and Drug Administration...
FDA Grants Orphan Drug Designation to Utidelone for Pancreatic Cancer
SAN FRANCISCO, Sept. 25, 2025 — Biostar Pharma’s core anticancer drug Utidelone has been granted Orphan Drug Designation (ODD)...
Advertisements
Tezspire Wins CHMP Backing for Chronic Rhinosinusitis in EU
September 22, 2025 – Brussels, Belgium – AstraZeneca and Amgen announced that the European Medicines Agency’s (EMA) Committee for...
EU Approves ROMVIMZA™, First Therapy for TGCT Patients in Europe
Brussels, Belgium – September 17, 2025 – In a landmark development for rare disease patients, the European Commission (EC)...
Hoth Therapeutics Advances HT-KIT After Preclinical Breakthrough
NEW YORK, Sept. 2, 2025 – Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical innovator, announced encouraging preclinical results...
Advertisement
